FibroBiologics (FBLG) Projected to Post Earnings on Wednesday

FibroBiologics (NASDAQ:FBLG) is expected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect FibroBiologics to post earnings of ($1.3340) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, April 30, 2026 at 7:00 AM ET.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.33) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Trading Down 14.7%

Shares of FibroBiologics stock opened at $0.99 on Tuesday. The business’s 50 day simple moving average is $3.49 and its 200-day simple moving average is $5.19. The stock has a market capitalization of $5.16 million, a price-to-earnings ratio of -0.14 and a beta of 1.16. FibroBiologics has a twelve month low of $0.95 and a twelve month high of $22.60.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a research report on Tuesday, April 21st. D. Boral Capital reiterated a “hold” rating on shares of FibroBiologics in a research report on Thursday, March 26th. Maxim Group cut FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Wall Street Zen upgraded FibroBiologics to a “sell” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $74.00.

Insider Buying and Selling

In other FibroBiologics news, CFO Jason Davis bought 3,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were purchased at an average cost of $8.20 per share, for a total transaction of $28,700.00. Following the transaction, the chief financial officer directly owned 3,500 shares in the company, valued at $28,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders purchased 9,574 shares of company stock valued at $72,886. 9.30% of the stock is owned by company insiders.

Institutional Trading of FibroBiologics

Several large investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. acquired a new stake in FibroBiologics in the 3rd quarter valued at approximately $191,000. Geode Capital Management LLC boosted its stake in FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after purchasing an additional 59,813 shares in the last quarter. Renaissance Technologies LLC boosted its stake in FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after purchasing an additional 171,800 shares in the last quarter. Jane Street Group LLC bought a new position in FibroBiologics during the 4th quarter valued at $34,000. Finally, Cerity Partners LLC boosted its stake in FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares in the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.